For teams · Mammography tracking software

Mammography tracking software compared: mammo tracking systems, mammography reporting system software, and what MQSA tracking costs

The short answer

Mammography tracking software is the system that closes the loop on every mammogram after the report is signed: it tracks positive and incomplete findings to a pathology outcome, sends the patient lay summary, and produces the annual medical outcomes audit that MQSA inspectors ask for. The main United States systems are MagView, Volpara Patient Hub (formerly MRS Aspen Breast), Intelerad IntelleScreen, eRAD MRS, Novarad MammoIQ and Mammotrac. Federal award records show real prices: buyers paid $219,980 for one VA mammography tracking and reporting system, and annual support on an installed system ran $61,853.98 to $134,922.10. Radiological.ai does not replace a tracking system; it is the assistant layer that triages and drafts on the imaging side of the same workflow.

Mammography tracking is the one piece of breast imaging software you buy because a federal regulation says you must. Under MQSA, every certified facility has to track positive mammographic findings, correlate them against the biopsy result, and produce a medical outcomes audit that the lead interpreting physician reviews and signs. That is a records obligation, not an imaging one, which is why it sits in a different system from your PACS and often from your RIS.

Every result on page one for this search is a vendor selling its own product, so this page does something different. It sets out what the rule actually requires, compares the systems on the axes that decide an inspection, and prices them against United States federal contract records rather than against marketing copy. Every dollar figure below is a real award you can look up. Radiological.ai is not a tracking system and does not claim to be one: it works upstream, triaging the worklist and drafting the structured report that the tracking system later files an outcome against.

Last updated September 2026

The Reading Station

Assistant ready

Worklist

SERIES 1 · AX

SLICE 24/64

SAMPLE STUDY

NOT FOR DIAGNOSTIC USE

W 80 · L 40

Structured report

Draft

Run the assistant to draft this report for review.

You review & sign

Illustrative sample · not a real patient study, not a diagnosis

Drafted in · you review & sign Worklist re-prioritized

Decision support for qualified clinicians. Radiological.ai does not provide a diagnosis and is not a substitute for professional judgment.

Run the assistant

Flag · prioritize · draft · you review and sign

X-RAY CT MRI BUILT WITH RADIOLOGISTS

Decision support not a diagnosis

You review & sign

Tracking closes the loop after the read, but the read itself is where turnaround and consistency are won or lost. Our AI mammography page covers the detection layer that works on the images themselves, which is a separate product category with a separate regulatory path, and structured radiology reporting covers the assessment and density fields that a tracking system depends on being coded consistently in the first place.

Most breast centers buy tracking as one line in a larger imaging budget. Radiology software pricing benchmarks the other categories against the same federal award data used above, radiology information system software covers the scheduling and charge capture that sits upstream of the tracking record, and radiology software contract negotiation covers the renewal and maintenance terms that decide what the second year costs. If the system you are renewing is the former MRS, our breakdown of MRS mammography reporting system pricing and alternatives covers who owns it now and what a replacement runs.

Primary source

What United States federal buyers actually paid for mammography tracking software

Every award below names mammography tracking, mammography reporting or the product by name in its own contract description. Nothing here is a vendor list price, and nothing here is inferred: these are signed federal awards, and each award ID can be looked up directly.

Federal award ID	Buyer and date	What the award record says it bought	Obligated amount
HT001521P5000	Defense Health Agency, Sep 2021	Mammography reporting system support (Volpara, now Lunit)	$438,810.00
36C24522P0340	Veterans Affairs, Mar 2022	Mammography tracking reporting system	$219,980.00
36C26222P2188	Veterans Affairs, Sep 2022	MagView MIS tracking and reporting system with implementation	$166,192.00
36C26223P1530	Veterans Affairs, Jun 2023	Mammography tracking and resulting system	$147,485.00
36C24825P0006	Veterans Affairs, Oct 2024	VISN 8 Aspen Breast upgrade, maintenance and support	$136,000.00
36C24822P0012	Veterans Affairs, Oct 2021	Aspen Breast software	$136,000.00
HT001519P0015	Defense Dept, Sep 2019	MagView annual software maintenance, Fort Belvoir Community Hospital	$123,345.00
36C26126P0051	Veterans Affairs, Nov 2025	Mammography tracking system for the VA National Teleradiology Program	$115,650.00
36C24524P0268	Veterans Affairs, Jan 2024	MagView mammography software support across VISN 05 medical centers	$104,902.54
36C26222P0276	Veterans Affairs, Dec 2021	MagView MIS tracking and resulting	$101,995.00
36C25725P0881	Veterans Affairs, Sep 2025	Mammography reporting system software and support services	$80,777.00
75H70525P00033	Health and Human Services, Mar 2025	Mammography tracking program and service support, White Earth Health Center	$71,064.10
36C26123P0687	Veterans Affairs, Mar 2023	MagView annual software support	$61,853.98
VA26117P3162	Veterans Affairs, Sep 2017	MagView software and maintenance	$55,490.00

Source: USAspending.gov prime award records, retrieved through the public API on September 6, 2026, filtered to contract award types A, B, C and D. Applied Software Inc is the contracting entity behind MagView, and its award descriptions name the product directly. Across its federal history, 60 awards explicitly name mammography or MagView, spanning 2007 through 2026 and totaling $2,467,859.87, with a median award of $24,318.66 and a range from $6,055.00 to $219,980.00. Two caveats worth stating plainly. Federal pricing reflects negotiated schedule terms and site counts that will not match a private quote, so read these as anchors rather than as your price. And the Volpara rows appear under the recipient name Lunit Americas, Inc. in current records, because Lunit acquired Volpara in May 2024; the product itself is the former MRS Aspen Breast.

Why it works

What your group gets with mammography tracking software

MQSA decides your feature list, not the vendor demo

The rule is narrower and more specific than most demos suggest. A certified facility must track mammograms interpreted as Suspicious or Highly suggestive of malignancy, determine whether a biopsy was performed, capture whether the specimen was benign or malignant, and report that back to the interpreting physician. That correlation has to be maintained and reviewed at least annually, and the lead interpreting physician signs the outcomes audit. When you evaluate a system, work backward from that sentence. Ask to see the audit report it generates, ask how pathology results get in when the biopsy happens somewhere else, and ask what happens to an incomplete BI-RADS 0 that never comes back. Those three answers separate the products far better than a feature grid does.

The 2023 MQSA final rule added notification work, and it is now enforced

The FDA issued the amended MQSA regulations on March 10, 2023, and enforcement began September 10, 2024. Reports must now carry an overall final assessment and an overall assessment of breast density, and every patient, including male patients, must receive a written lay summary containing density information. When the assessment is Suspicious or Highly suggestive of malignancy, the report goes to the provider and the lay summary to the patient within 7 calendar days of interpretation. Facilities must also list their own accredited name and address rather than the parent network name. That 7 day clock is the part that breaks a manual process: it is a per patient deadline across every location, and it is the single most common reason a facility that managed on spreadsheets stops managing on spreadsheets.

Tracking software is not a cleared device, and that is the right answer

It is worth knowing which parts of a breast imaging stack carry FDA clearance and which do not, because vendors sometimes blur the line. Searching the openFDA 510(k) database by applicant name on September 6, 2026 returns zero clearances for MagView and zero for MRS Systems, against 2 for Volpara, 8 for ScreenPoint Medical, 15 for iCAD and 127 for Hologic. That is not a knock on the tracking vendors. A tracking and reporting system manages records and correspondence, so it is not a diagnostic device and does not need a clearance. The software that reads the image is a different product category with a different regulatory path. If a tracking vendor markets an AI detection feature, ask for the K number of that specific feature, not of the platform.

What it handles

Flagged, prioritized and drafted for your review

The assistant pre-reads each study, surfaces a region of interest for review, re-prioritizes the worklist, and drafts the structured report in your template. You confirm, edit and sign.

Triages the imaging worklist so suspected time-critical studies surface first
Flags suspected findings for the radiologist to review before the report is signed
Drafts the structured report into your own template, including the assessment fields
Hands a clean, consistently coded report to whichever tracking system files the outcome
Connects over standard DICOM and HL7 alongside your existing PACS and RIS
The radiologist reviews every flag and signs every report

MAMMOGRAPHY TRACKING SOFTWARE STAT

Region of interest flagged for review

A focal region is surfaced on the sample study for the radiologist to review. The assistant does not characterize it as a diagnosis.

Draft impression

Suspected finding flagged for radiologist review. Correlate clinically and confirm. Draft for review and sign-off.

Illustrative sample · not for diagnostic use You review & sign

Why Radiological.ai

One assistant across the whole read

Not three vendors stitched together. Flag, prioritize and draft in one calm pane, on X-ray, CT and MRI, with the radiologist signing every study.

Flags suspected findings

A second set of eyes surfaces regions of interest for review on every study, so a suspected finding is less likely to slip past late in a shift.

Prioritizes the worklist

Suspected-critical studies move to the top, so urgent reads surface ahead of routine follow-ups across your sites and shifts.

Drafts the report

A structured draft arrives in your template, ready to edit and sign. The draft saves the typing and the measuring, never the judgment.

Good questions

Questions about mammography tracking software

Mammography tracking software is a records system that follows every mammogram after interpretation until its outcome is known. It tracks positive and incomplete findings to a pathology result, generates and sends patient lay summaries, monitors recall and cancer detection rates, and produces the annual medical outcomes audit required under MQSA. It is separate from PACS, which stores and displays the images, and from a RIS, which schedules and bills them.

A tracking system is required; specific software is not. MQSA requires each certified facility to maintain a system that tracks positive mammographic findings, correlates them with biopsy results, and reports the correlation back to the interpreting physician, reviewed at least annually. The regulation does not name a product or require software at all. In practice, the 2023 final rule added per patient lay summaries and a 7 calendar day deadline for suspicious findings, which is what pushes most facilities off manual tracking.

Federal award records give the clearest public anchors. Buyers paid $219,980 for one VA mammography tracking and reporting system and $166,192 for a MagView deployment including implementation, while annual support on an installed system ran between $61,853.98 and $134,922.10. Across 60 federal awards naming mammography or MagView, the median was $24,318.66, reflecting how many are small annual renewals. Private quotes vary with site count and volume.

Lunit owns it. MRS Systems, Inc., founded in Seattle in 1985, built the Aspen Breast reporting platform and was acquired by Volpara Health in 2019. Lunit then acquired Volpara in May 2024 for approximately $194 million, and Aspen Breast was renamed Volpara Patient Hub. Federal contract records still show the original product name, with awards for Aspen Breast software now listed under the recipient Lunit Americas, Inc.

They solve different problems and are rarely the same product. A PACS stores, retrieves and displays the images so a radiologist can read them. A mammography tracking system holds no images: it manages the record of what was found, whether the patient came back, what the biopsy showed, and what was mailed to whom. An inspection asks the tracking system for its outcomes audit, not the PACS.

At minimum it must correlate mammograms interpreted as Suspicious or Highly suggestive of malignancy against the biopsy results the facility obtains, distinguish benign from malignant, and report those results back to each interpreting physician. Facilities are inspected on it annually and the lead interpreting physician reviews and signs it. Most tracking systems generate the report on demand; the work you cannot automate is getting outside pathology results back into the record.

No, and the leading products do not have one. An openFDA 510(k) search by applicant on September 6, 2026 returned zero clearances for MagView and zero for MRS Systems. Tracking and reporting software manages records and correspondence rather than interpreting images, so it falls outside the device pathway. Image analysis software is different: Volpara holds 2 clearances, ScreenPoint 8, iCAD 15 and Hologic 127.

Read every AI radiology question

Explore more